Literature DB >> 20437198

Three polymorphisms in interleukin-1β gene and risk for breast cancer: a meta-analysis.

Xiaoan Liu1, Zhanwei Wang, Jinhua Yu, Gang Lei, Shui Wang.   

Abstract

Interleukin-1β (IL-1β), which is involved in inflammatory and immunological responses, plays an important role in the development and progression of breast cancer. Three functional single nucleotide polymorphisms (SNPs) identified in IL-1β gene are thought to influence breast cancer risk. The results of the association between IL-1β polymorphisms and breast cancer remain inconsistent. Therefore, we conducted a meta-analysis of eight case-control studies with rs1143627 (T > C), rs16944 (C > T), and rs1143634 (C > T). We found that the variant CC genotype of rs1143627 was associated with a significantly increased breast cancer risk (CC vs. TT: OR = 1.37, 95% CI = 1.10-1.70, P = 0.22 for heterogeneity; the recessive model CC vs. TT/TC: OR = 1.40, 95% CI = 1.17-1.67, P = 0.49 for heterogeneity). For rs16944 (C > T) and rs1143634 (C > T), no significant associations were found in all genetic models. In conclusion, the present meta-analysis suggests that rs1143627 is associated with breast cancer risk.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20437198     DOI: 10.1007/s10549-010-0910-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  18 in total

1.  Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study.

Authors:  Martha L Slattery; Jennifer S Herrick; Gabriella Torres-Mejia; Esther M John; Anna R Giuliano; Lisa M Hines; Mariana C Stern; Kathy B Baumgartner; Angela P Presson; Roger K Wolff
Journal:  Carcinogenesis       Date:  2014-03-26       Impact factor: 4.944

2.  The Immunogenetics of Melanoma.

Authors:  Farzaneh Darbeheshti
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis.

Authors:  Li-Sheng Wu; Hong Wang; Xiao-Ping Geng
Journal:  Exp Ther Med       Date:  2011-11-21       Impact factor: 2.447

Review 4.  Obesity and cancer: inflammation bridges the two.

Authors:  Ryan Kolb; Fayyaz S Sutterwala; Weizhou Zhang
Journal:  Curr Opin Pharmacol       Date:  2016-07-16       Impact factor: 5.547

5.  Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver.

Authors:  Kathrin Klein; Stefan Winter; Miia Turpeinen; Matthias Schwab; Ulrich M Zanger
Journal:  Front Pharmacol       Date:  2010-11-02       Impact factor: 5.810

6.  The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis.

Authors:  Wen-Bin Zhou; Dan-Qing Xue; Xiao-An Liu; Qiang Ding; Shui Wang
Journal:  J Cancer Res Clin Oncol       Date:  2011-04-17       Impact factor: 4.553

7.  Innegligible musculoskeletal disorders caused by zoledronic acid in adjuvant breast cancer treatment: a meta-analysis.

Authors:  Wen-Bin Zhou; Peng-Ling Zhang; Xiao-An Liu; Tao Yang; Wei He
Journal:  J Exp Clin Cancer Res       Date:  2011-08-04

8.  IL1 receptor antagonist gene IL1-RN variable number of tandem repeats polymorphism and cancer risk: a literature review and meta-analysis.

Authors:  Ying Zhang; Changming Liu; Huiping Peng; Jianzhi Zhang; Quanlin Feng
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

9.  Comparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detection.

Authors:  Zoi Lanara; Efstathia Giannopoulou; Marta Fullen; Evangelos Kostantinopoulos; Jean-Christophe Nebel; Haralabos P Kalofonos; George P Patrinos; Cristiana Pavlidis
Journal:  Hum Genomics       Date:  2013-06-05       Impact factor: 4.639

10.  Interleukin-1 beta inhibition with canakinumab and reducing lung cancer-subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS).

Authors:  David Crossman; Alexander M K Rothman
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 3.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.